MJ210 is an orally active and blood-brain barrier-permeable modulator of the NF-kappaB and MAPK pathways, exhibiting neuroprotective properties. In vitro, 5 µM MJ210 can increase the survival rate of rotenone-treated SH-SY5Y cells to 81.9% and reduce levels of ROS. In vivo, 5 mg/kg MJ210 improves motor dysfunction in rat models of Parkinsons disease. MJ210 is useful for research in neurological disorders, including Parkinsons disease.
